MAPK14 and Behcet disease: In addition, EGb761 treatment at 48 hours before brain death significantly reduced the levels of p-JNK-MAPK (P < 0.01), p-p38-MAPK (P < 0.05), and p-STAT3 (P < 0.01) as compared to BD group.